{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:49:01Z","timestamp":1789343341553,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003484","name":"Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003484","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Gastrointestinal (non-pancreatic) neuroendocrine tumors (GI-NETs) represent a rare but increasingly common tumor entity. Prognosis and biological behavior of these tumors is extremely heterogenous and largely dependent on the specific tumor site, stage and differentiation. However, systematic data on the epidemiology of GI-NET, especially in terms of geographic distributions are missing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used the Oncology Dynamics database (IQVIA) to identify a total of 1354 patients with GI-NET from four European countries (Germany, France, Spain, UK) and compared them with regard to major patient and tumor related characteristics including patients\u2019 age, sex, tumor stage, tumor grading and differentiation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of the analyzed 1354 NET patients, 535 were found in the UK (39.5%), 289 in Germany (21.3%), 283 in Spain (20.9%) and 247 in France (18.2%). More patients were male than female (53.8% vs. 46.2%) with no significant differences between the analyzed countries. In contrast, the age distribution varied between the different countries, with the highest number of patients identified in the age groups of 61\u201370\u00a0years (31.0%) and 71\u201380\u00a0years (30.7%). The vast majority of patients showed a tumor origin in the small intestine, in German patients NET of the large intestine were slightly overrepresented and NET of the stomach underrepresented compared to all other countries. More than 80% of patients had stage IV disease at the time of diagnosis. Regarding tumor histology, most tumors showed a G2 tumor; interestingly, a G3 grading was found in 40.9% of patients in Germany (Ki-67\u2009&gt;\u200920%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The distribution of important patient- and tumor-specific characteristics of neuroendocrine tumors shows regional differences in four major European countries. These data may help to better understand the specific epidemiology of GI-NET in Europe.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-022-04003-3","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T08:03:50Z","timestamp":1651046630000},"page":"1411-1416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Distribution of gastrointestinal neuroendocrine tumors in Europe: results from a retrospective cross-sectional study"],"prefix":"10.1007","volume":"149","author":[{"given":"Sven H.","family":"Loosen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Kostev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Jann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Tetzlaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Krieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram T.","family":"Knoefel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Fluegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Luedde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Krieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1409-7697","authenticated-orcid":false,"given":"Christoph","family":"Roderburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"4003_CR1","doi-asserted-by":"publisher","first-page":"e770","DOI":"10.1200\/JOP.19.00507","volume":"16","author":"P Chambers","year":"2020","unstructured":"Chambers P, Man KKC, Lui VWY, Mpima S, Nasuti P, Forster MD, Wong ICK (2020) Understanding molecular testing uptake across tumor types in eight countries: results from a multinational cross-sectional survey. JCO Oncol Pract 16:e770\u2013e778","journal-title":"JCO Oncol Pract"},{"key":"4003_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000509864","volume":"111","author":"K Detjen","year":"2021","unstructured":"Detjen K, Hammerich L, Ozdirik B, Demir M, Wiedenmann B, Tacke F, Jann H, Roderburg C (2021) Models of gastroenteropancreatic neuroendocrine neoplasms: current status and future directions. Neuroendocrinology 111:217\u2013236","journal-title":"Neuroendocrinology"},{"key":"4003_CR3","doi-asserted-by":"crossref","unstructured":"Kasajima A, Konukiewitz B, Schlitter AM, Weichert W, Kloppel G (2021) An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features. Virchows Arch","DOI":"10.1007\/s00428-021-03202-6"},{"key":"4003_CR4","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ejca.2011.08.012","volume":"48","author":"CM Korse","year":"2012","unstructured":"Korse CM, Taal BG, Vincent A, van Velthuysen ML, Baas P, Buning-Kager JC, Linders TC, Bonfrer JM (2012) Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments. Eur J Cancer 48:662\u2013671","journal-title":"Eur J Cancer"},{"key":"4003_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11307-014-0795-3","volume":"17","author":"C Kratochwil","year":"2015","unstructured":"Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, Mier W, Haberkorn U, Giesel FL (2015) SUV of [68Ga]DOTATOC-PET\/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol 17:313\u2013318","journal-title":"Mol Imaging Biol"},{"key":"4003_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.breast.2016.12.002","volume":"32","author":"P Marchetti","year":"2017","unstructured":"Marchetti P, Maass N, Gligorov J, Berger K, MacDougall F, Montonen J, Lewis J (2017) Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: a European perspective. Breast 32:247\u2013255","journal-title":"Breast"},{"key":"4003_CR7","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, Oberg K, Falconi M, Krenning EP, Sundin A, Perren A, Berruti A, clinicalguidelines@esmo.org, E.G.C.E.a (2020) Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:844\u2013860","journal-title":"Ann Oncol"},{"key":"4003_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.32074\/1591-951X-542","volume":"113","author":"G Pelosi","year":"2021","unstructured":"Pelosi G, Travis WD (2021) The Ki-67 antigen in the new 2021 World Health Organization classification of lung neuroendocrine neoplasms. Pathologica 113:377\u2013387","journal-title":"Pathologica"},{"key":"4003_CR9","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41574-020-0391-3","volume":"16","author":"G Rindi","year":"2020","unstructured":"Rindi G, Wiedenmann B (2020) Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine. Nat Rev Endocrinol 16:590\u2013607","journal-title":"Nat Rev Endocrinol"},{"key":"4003_CR10","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","volume":"31","author":"G Rindi","year":"2018","unstructured":"Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M, El-Naggar AK et al (2018) A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 31:1770\u20131786","journal-title":"Mod Pathol"},{"key":"4003_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000403785","volume":"44","author":"J Strosberg","year":"2015","unstructured":"Strosberg J, Goldman J, Costa F, Pavel M (2015) The role of chemotherapy in well-differentiated gastroenteropancreatic neuroendocrine tumors. Front Horm Res 44:239\u2013247","journal-title":"Front Horm Res"},{"key":"4003_CR12","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.3390\/ijms20123049","volume":"20","author":"AK Stueven","year":"2019","unstructured":"Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H (2019) Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future. Int J Mol Sci 20:3049","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"4003_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000080731","volume":"80","author":"BG Taal","year":"2004","unstructured":"Taal BG, Visser O (2004) Epidemiology of neuroendocrine tumours. Neuroendocrinology 80(Suppl 1):3\u20137","journal-title":"Neuroendocrinology"},{"key":"4003_CR14","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s12029-011-9349-y","volume":"43","author":"Z Zhao","year":"2012","unstructured":"Zhao Z, Pelletier E, Barber B, Bhosle M, Wang S, Klingman D, Gao S (2012) Major surgery in patients with metastatic colorectal cancer in Western Europe. J Gastrointest Cancer 43:456\u2013461","journal-title":"J Gastrointest Cancer"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04003-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04003-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04003-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T23:59:13Z","timestamp":1679875153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04003-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["4003"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04003-3","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]},"assertion":[{"value":"21 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The \u201cDisease Analyzer\u201d database, used for analysis, contains anonymized electronic patient records. Patient data were analyzed in aggregated form without individual data being available. An individual consent form was not obtained following national and European legislation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors approved the publication of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}